Deucrictibant Phase 2 HAE Prophylaxis Success: AAAAI 2024 Presentation

Pharvaris, a clinical-stage pharmaceutical company, is dedicated to the development of innovative oral medications for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent swelling episodes. The firm's mission is to liberate HAE patients from the burdens of their symptoms, attacks, and the need for injections, by advancing oral alternatives that offer a new standard of care.

The company's lead candidate, deucrictibant, is an oral antagonist of the bradykinin B2 receptor, which plays a pivotal role in the pathophysiology of HAE. Deucrictibant has demonstrated promising results in clinical trials, showing a significant reduction in the frequency of HAE attacks. In a Phase 2 study known as CHAPTER-1, deucrictibant was found to reduce the monthly attack rate by 84.5% at a dosage of 40 mg/day and by 79.3% at 20 mg/day, compared to a placebo. The drug was well-tolerated, with mild adverse events reported, and no serious adverse events leading to discontinuation or withdrawal from the study.

Pharvaris is also committed to understanding the barriers faced by HAE patients in deciding whether to treat an attack with on-demand therapy. This insight is crucial for the company's goal of pioneering patient-centric science and offering choices to those living with HAE.

Deucrictibant is formulated in two oral forms: a capsule for rapid onset in acute situations and an extended-release tablet for sustained efficacy in prophylactic treatment. The company's expertise in rare diseases and HAE, combined with a talented team, positions Pharvaris at the forefront of developing efficacious, safe, and easy-to-administer treatments for all HAE subtypes.

Pharvaris' dedication to improving the lives of HAE patients is evident through its ongoing research and development efforts. The company's legacy in HAE, scientific knowledge, and core values drive its passion to provide patients with a range of treatment options that align with their individual needs and preferences. As Pharvaris continues to advance its pipeline, it aims to transform the landscape of HAE treatment, offering hope and new possibilities for those affected by this condition.